Abstract
Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.
Original language | English |
---|---|
Pages (from-to) | 24-28 |
Journal | Clinical and Translational Radiation Oncology |
Volume | 13 |
DOIs | |
Publication status | Published - 2018 Nov |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2018 The Authors
Subject classification (UKÄ)
- Radiology, Nuclear Medicine and Medical Imaging
- Cancer and Oncology
Free keywords
- EBUS
- Endoscopic ultrasound
- Image-guided radiotherapy
- Liquid fiducial marker
- NSCLC